Armando Anido

2021

In 2021, Armando Anido earned a total compensation of $2.2M as Chairman of the Board and CEO at Zynerba Pharmaceuticals, a 49% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$379,675
Option Awards$446,472
Salary$603,000
Stock Awards$772,643
Other$10,685
Total$2,212,475

Anido received $772.6K in stock awards, accounting for 35% of the total pay in 2021.

Anido also received $379.7K in non-equity incentive plan, $446.5K in option awards, $603K in salary and $10.7K in other compensation.

Rankings

In 2021, Armando Anido's compensation ranked 5,662nd out of 12,415 executives tracked by ExecPay. In other words, Anido earned more than 54.4% of executives.

ClassificationRankingPercentile
All
5,662
out of 12,415
54th
Division
Manufacturing
2,399
out of 5,505
56th
Major group
Chemicals And Allied Products
1,044
out of 2,375
56th
Industry group
Drugs
932
out of 2,096
56th
Industry
Pharmaceutical Preparations
671
out of 1,546
57th
Source: SEC filing on April 25, 2022.

Anido's colleagues

We found two more compensation records of executives who worked with Armando Anido at Zynerba Pharmaceuticals in 2021.

2021

Terri Sebree

Zynerba Pharmaceuticals

President

2021

James Fickenscher

Zynerba Pharmaceuticals

Chief Financial Officer

News

You may also like